Exploring the role of RET 5’ fusion partners in regulating signaling and response to therapy in novel RET-rearranged lung cancer models
RET rearrangements occur in 1-2% of lung adenocarcinomas as well as other malignancies and are promising targets for tyrosine kinase inhibitors. Non-small cell lung cancer patients with activating mutations in ALK, EGFR and ROS1 have benefitted significantly from targeted inhibitors, yet clinical trials with multi-kinase RET inhibitors have had disappointing results. Recently, more specific RET inhibitors have been showing early success in clinical trials, but have revealed differential responses in patients with different RET 5’ partners. This work addresses the molecular mechanisms regulating ...
(For more, see "View full record.")